Ophthalmic Surgery, Lasers and Imaging Retina

Erratum Free

Erratum for “Reduction in Retinal Thickness Fluctuations After Treatment With Fluocinolone Acetonide Implant for DME: A Post-Hoc Analysis of the USER Study”

The article “Reduction in Retinal Thickness Fluctuations After Treatment With Fluocinolone Acetonide Implant for DME: A Post-Hoc Analysis of the USER Study” by Christopher D. Riemann, MD; Alexander M. Eaton, MD; and Antonio Cutino, COT, which was published in the May issue of OSLI Retina (volume 51, number 5, pp. 298–306), has been amended to include factual corrections. An error was identified subsequent to its original publication. The caption for Figure 4 should have included the statement that data for Patient 1 were courtesy of Dilsher S. Dhoot, MD, and that data for Patient 2 were courtesy of Singh P, Chedid A, Deuchler SK, Kohnen T, Muller M, Koch FH. The efficacy and safety outcomes of the 0.19 mg fluocinolone acetonide implant after prior treatment with the 0.7mg dexamethasone implant in patients with diabetic macular edema. Int Med Case Rep J. 2018;15(11): 265–269. The online article and its erratum are considered the version of record.

To view the article, click here.

The effect of transitioning from discontinuous therapies to fluocinolone acetonide (FAc) implant treatment on central subfield thickness (CST), retinal thickness amplitude (RTA), retinal thickness standard deviation (RTSD), and visual acuity (VA) in two illustrative patient case studies (not from the USER dataset). Patient 1 data courtesy of Dhoot DS. Case data presented at: Scientific Advisory Board meeting, American Academy of Ophthalmology Annual Meeting; October 28, 2018; Chicago, IL. Patient 2 data courtesy of Singh P, Chedid A, Deuchler SK, Kohnen T, Muller M, Koch FH. The efficacy and safety outcomes of the 0.19 mg fluocinolone acetonide implant after prior treatment with the 0.7mg dexamethasone implant in patients with diabetic macular edema. Int Med Case Rep J. 2018;15(11): 265–269.Anti-VEGF = anti-vascular endothelial growth factor; ETDRS = Early Treatment Diabetic Retinopathy Study

Figure 4.

The effect of transitioning from discontinuous therapies to fluocinolone acetonide (FAc) implant treatment on central subfield thickness (CST), retinal thickness amplitude (RTA), retinal thickness standard deviation (RTSD), and visual acuity (VA) in two illustrative patient case studies (not from the USER dataset). Patient 1 data courtesy of Dhoot DS. Case data presented at: Scientific Advisory Board meeting, American Academy of Ophthalmology Annual Meeting; October 28, 2018; Chicago, IL. Patient 2 data courtesy of Singh P, Chedid A, Deuchler SK, Kohnen T, Muller M, Koch FH. The efficacy and safety outcomes of the 0.19 mg fluocinolone acetonide implant after prior treatment with the 0.7mg dexamethasone implant in patients with diabetic macular edema. Int Med Case Rep J. 2018;15(11): 265–269.

Anti-VEGF = anti-vascular endothelial growth factor; ETDRS = Early Treatment Diabetic Retinopathy Study

Authors

10.3928/23258160-20200702-01

Sign up to receive

Journal E-contents